Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc at Truist Securities Life Sciences Summit (May Series) Transcript

May 05, 2021 / 04:10PM GMT
Release Date Price: $29.22 (-3.15%)
Asthika Sarith Goonewardene
Truist Securities, Inc., Research Division - Research Analyst

Hello, everyone, and welcome to our next session. My name is Asthika Goonewardene. We are thrilled to have the folks from Iovance with us on this installment of the Truist Securities Life Sciences Summit.

From the company, we have Maria Fardis, President and CEO, joining us today. Maria, welcome. It's a pleasure to have you here, first time on our platform.

Maria Fardis

Thank you for the invite. Much appreciate the initiation of the coverage as well.

Asthika Sarith Goonewardene
Truist Securities, Inc., Research Division - Research Analyst

Yes. I might as well mention that. So we actually just freshly initiated coverage on Iovance with a buy just on Monday. We are definitely just about the deal space, and we'll talk about that more. Before we start, let me read out my disclosure, and I'm going to hand over to Maria to do some introductions to the company.

So this call is arranged by Truist Securities Research for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot